Search News & Insights
Matheson advises Auxilium on its $2.6 billion merger with Endo
Matheson advised Auxilium Pharmaceuticals Inc. on its $2.6 billion merger with Endo International plc.
The transaction, which was announced on 9 October 2014, has been unanimously approved by the boards of directors of both companies. The transaction is valued at USD 2.6 billion, including the repayment and assumption of debt. The deal is expected to close in H1 2015 and is subject to shareholder and regulatory approval.
The Matheson team included corporate partners Tim Scanlon and George Brady, tax partner Shane Hogan and Head of US Offices, John Ryan. This continues Matheson’s track record of advising on high profile international M&A transactions. Matheson recently advised Questcor Pharmaceuticals on its $5.6 billion merger with Mallinckrodt and is advising Perella Weinberg Partners as financial adviser to Medtronic on its $42.9 billion acquisition of Covidien. Matheson also advised Actavis on its $8.5 billion acquisition of Dublin-based Warner Chilcott as well as advising Royalty Pharma on its $6.5 billion hostile bid for Elan Corporation, the Irish biotechnology company in 2013.